ZoeNCure Therapeutics INR 20 Crore Seed Round

ZoeNCure Therapeutics has announced the successful closing of an INR 20 Crore (approx. $2.4 Million USD) seed financing round. The HNI Tyagi Family, based in Gurugram, led the investment, with participation from angel co-investors.

This follows a prior INR 2.5 Crore pre-seed investment from the same family, bringing the company’s total equity raised to INR 22.5 Crore.

ZoeNCure Therapeutics, an oncology biotechnology company headquartered in New Delhi, is developing targeted cancer therapies, including next-generation Antibody Drug Conjugates (ADCs).

Its platform combines advanced antibody targeting with dual-mechanism cytotoxic payloads designed to overcome treatment resistance.

The capital will be used to advance the company’s lead ADC candidate toward first-in-human Phase 1 clinical studies for severe liver and gastrointestinal cancers, specifically hepatocellular carcinoma (HCC).

Funding will also support preclinical studies, CMC scale-up, and regulatory submissions to India’s Central Drugs Standard Control Organisation (CDSCO).

“ZoeNCure has demonstrated exceptional execution speed, scientific discipline, and capital efficiency since our initial pre-seed investment,” said Mr. Manoj Tyagi, a representative of the Tyagi Family. “We are proud to double down on our commitment to ZoeNCure as they prepare to transition their novel cancer therapies from the bench into clinical evaluation.”